MD Anderson researchers have discovered that metastatic cancer cells in the brain upregulate expression of the EZH2 gene to activate a previously unknown pathway and recruit immune-suppressive neutrophils to the brain, allowing metastatic cells to thrive. The study, published in Science Translational Medicine, suggests that targeting this neutrophil recruitment may be a useful strategy for treating brain metastases.
“To gain...
Two studies presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting highlighted MD Anderson’s commitment to holistic...
Updated results from two MD Anderson clinical trials presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting indicate...
Findings from three studies led by researchers at MD Anderson suggest that new combination therapies are safe and effective against various types of leukemia. The investigators believe that the promising data about the use of these therapeutic regimens may lead to new standards of care and more leukemia treatment options. Results from the clinical trials were presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting...
Several MD Anderson-led studies at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting focus on using immunotherapy to provide...
Julia Pitts tried all the standard treatment options with her local physicians after she was diagnosed with metastatic uterine cancer in 2015...
Mutations in the BRCA 1 or 2 genes significantly increase an individual’s risk of developing breast cancer, as well as several other cancer...
In an analysis of three clinical trials, the targeted therapy larotrectinib resulted in a 79% overall response rate and median overall survival...
An MD Anderson Phase I clinical trial demonstrated that a combination therapy using WNT974, a drug that targets the WNT pathway in cancer,...
A Phase I chemoprevention clinical trial led by MD Anderson researchers found that naproxen, an over-the-counter anti-inflammatory drug, is...